Next Article in Journal
Cell Death Pathways in Photodynamic Therapy of Cancer
Previous Article in Journal
Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives
Previous Article in Special Issue
Neoadjuvant Therapy in Patients with Pancreatic Cancer: A Disappointing Therapeutic Approach?
Cancers 2011, 3(2), 2501-2515; doi:10.3390/cancers3022501
Article

Activation of PDGFr-β Signaling Pathway after Imatinib and Radioimmunotherapy Treatment in Experimental Pancreatic Cancer

1
, 2
, 2
, 2
 and 2,*
Received: 4 February 2011; in revised form: 25 April 2011 / Accepted: 17 May 2011 / Published: 25 May 2011
(This article belongs to the Special Issue Pancreatic Cancer)
View Full-Text   |   Download PDF [539 KB, updated 31 May 2011; original version uploaded 25 May 2011]   |   Browse Figures
Abstract: Pancreatic cancer does not respond to a single-agent imatinib therapy. Consequently, multimodality treatments are contemplated. Published data indicate that in colorectal cancer, imatinib and radioimmunotherapy synergize to delay tumor growth. In pancreatic cancer, the tumor response is additive. This disparity of outcomes merited further studies because interactions between these modalities depend on the imatinib-induced reduction of the tumor interstitial fluid pressure. The examination of human and murine PDGFr-β/PDGF-B pathways in SW1990 pancreatic cancer xenografts revealed that the human branch is practically dormant in untreated tumors but the insult on the stromal component produces massive responses of human cancer cells. Inhibition of the stromal PDGFr-β with imatinib activates human PDGFr-β/PDGF-B signaling loop, silent in untreated xenografts, via an apparent paracrine rescue pathway. Responses are treatment- and time-dependent. Soon after treatment, levels of human PDGFr-β, compared to untreated tumors, are 3.4×, 12.4×, and 5.7× higher in imatinib-, radioimmunotherapy + imatinib-, and radioimmunotherapy-treated tumors, respectively. A continuous 14-day irradiation of imatinib-treated xenografts reduces levels of PDGFr-β and phosphorylated PDGFr-β by 5.3× and 4×, compared to earlier times. Human PDGF-B is upregulated suggesting that the survival signaling via the autocrine pathway is also triggered after stromal injury. These findings indicate that therapies targeting pancreatic cancer stromal components may have unintended mitogenic effects and that these effects can be reversed when imatinib is used in conjunction with radioimmunotherapy.
Keywords: pancreatic cancer; PDGFr-β; PDGF-B; imatinib; radioimmunotherapy; radiation pancreatic cancer; PDGFr-β; PDGF-B; imatinib; radioimmunotherapy; radiation
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Abe, M.; Kortylewicz, Z.P.; Enke, C.A.; Mack, E.; Baranowska-Kortylewicz, J. Activation of PDGFr-β Signaling Pathway after Imatinib and Radioimmunotherapy Treatment in Experimental Pancreatic Cancer. Cancers 2011, 3, 2501-2515.

AMA Style

Abe M, Kortylewicz ZP, Enke CA, Mack E, Baranowska-Kortylewicz J. Activation of PDGFr-β Signaling Pathway after Imatinib and Radioimmunotherapy Treatment in Experimental Pancreatic Cancer. Cancers. 2011; 3(2):2501-2515.

Chicago/Turabian Style

Abe, Michio; Kortylewicz, Zbigniew P.; Enke, Charles A.; Mack, Elizabeth; Baranowska-Kortylewicz, Janina. 2011. "Activation of PDGFr-β Signaling Pathway after Imatinib and Radioimmunotherapy Treatment in Experimental Pancreatic Cancer." Cancers 3, no. 2: 2501-2515.


Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert